SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), an organization devoted to remodeling the lives of these affected by most cancers, at this time introduced that it’ll current preclinical information in a poster on the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The assembly can be held from Oct. 26-28, 2022.
The poster will embrace preclinical information demonstrating that Kronos Bio’s internally found oral CDK9 inhibitor, KB-0742 induced regressions in a preclinical mannequin of MYCN-amplified neuroblastoma tumors and inhibited development in patient-derived xenograft (PDX) fashions of transcriptionally addicted Ewing sarcoma (EW) and alveolar rhabdomyosarcoma (ARMS).
This is the primary preclinical evaluation to assist the investigational compound’s potential in pediatric tumors. KB-0742 is being developed for the remedy of MYC-amplified and transcriptionally addicted stable tumors and is at present being assessed as a part of an ongoing Phase 1/2 research. Kronos Bio stays on monitor to present an replace on the research, together with the Recommended Phase 2 Dose (RP2D) within the fourth quarter.
The summary is now obtainable on the convention web site. Details of the poster presentation are as follows:
Poster Title: Regulation of oncogenic transcription and tumor development in pediatric cancers by the CDK9 inhibitor KB-0742
Abstract Number: PB088
Date and Time: Oct. 27, 10 a.m. Central European Time
About KB-0742
KB-0742 is a extremely selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in improvement for the remedy of MYC-amplified stable tumors. CDK9 is a world regulator of transcription and performs an important function in each the expression and performance of MYC, a well-characterized transcription issue and a long-recognized driver of most cancers that’s amplified in roughly 30% of stable tumors, together with these affecting the lungs, ovaries and breast. KB-0742 was generated and optimized from a compound that was recognized utilizing the corporate’s proprietary small molecule microarray (SMM) screening platform.
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical firm that’s advancing three investigational compounds in medical trials for sufferers with most cancers. The firm’s lead compound, the SYK inhibitor entospletinib, is being evaluated within the registrational Phase 3 AGILITY trial as a remedy for sufferers with newly identified NPM1-mutated acute myeloid leukemia (AML). The firm can be creating the CDK9 inhibitor, KB-0742, as a remedy for MYC-amplified stable tumors and lanraplenib, a next-generation SYK inhibitor being assessed in sufferers with FLT3-mutated AML. The firm’s scientific focus is on creating medicines that concentrate on the dysregulated transcription that’s the hallmark of most cancers and different critical illnesses.
Kronos Bio is predicated in San Mateo, Calif., and has a analysis facility in Cambridge, Mass. For extra data, go to www.kronosbio.com or observe the corporate on LinkedIn.
Forward-Looking Statements
Statements on this press launch that aren’t statements of historic truth are forward-looking statements for functions of the protected harbor provisions of the Private Securities Litigation Reform Act of 1995. The press launch, in some instances, makes use of phrases comparable to “on track to,” “plan,” “potential,” “will” or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. Forward-looking statements embrace statements relating to Kronos Bio’s intentions, beliefs, projections, outlook, analyses or present expectations regarding, amongst different issues, Kronos Bio’s plan to present an replace and really useful Phase 2 dose for the KB-0742 research, KB-0742’s potential in pediatric tumors and different statements that aren’t historic truth. Actual outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements because of varied dangers and uncertainties, together with, with out limitation: whether or not Kronos Bio can be ready to progress the Phase 1/2 medical trial of KB-0742 on the timeline anticipated, together with due to dangers related to the COVID-19 pandemic and dangers inherent within the medical improvement of novel therapeutics; dangers associated to Kronos Bio’s lack of expertise as an organization in conducting medical trials; the danger that outcomes of preclinical research and early medical trials should not essentially predictive of future outcomes; and dangers related to the sufficiency of Kronos Bio’s money assets and wish for further capital. These and different dangers are described in higher element in Kronos Bio’s filings with the Securities and Exchange Commission (SEC), together with below the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 4, 2022. Any forward-looking statements which might be made on this press launch communicate solely as of the date of this press launch and are primarily based on administration’s assumptions and estimates as of such date. Except as required by legislation, Kronos Bio assumes no obligation to replace the forward-looking statements whether or not because of new data, future occasions or in any other case, after the date of this press launch.
Company Contact:
Marni Kottle
Senior Vice President, Corporate Communications & Investor Relations
415-218-7111
[email protected]
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
[email protected]
Media:
Sheryl Seapy
Real Chemistry
949-903-4750
[email protected]
